Lung Ultrasound-Guided Fluid Deresuscitation in ICU Patients
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jan 11, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how using a special imaging tool called lung ultrasound can help doctors better manage excess fluid in the lungs of patients who are on invasive mechanical ventilation in the intensive care unit (ICU). The researchers believe that guiding treatment with lung ultrasound will allow patients to be taken off the ventilator sooner than if doctors rely on their usual methods. The study will involve around 1,000 adult patients who are expected to need help breathing for more than 24 hours after joining the trial.
To participate in this study, patients must be admitted to one of the participating ICUs and have been on a ventilator for less than 24 hours. However, those under 18 years old, pregnant individuals, or patients with certain medical conditions may not be eligible. Participants will be randomly assigned to one of two groups: one group will have their fluid management guided by lung ultrasound, while the other group will follow standard treatment practices. This trial is still recruiting participants, and it aims to see if the ultrasound-guided approach can lead to more days without needing the ventilator.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admission to one of the participating ICUs;
- • Invasively ventilated for less than 24 hours at randomization;
- • Expected to be under invasive ventilation for longer than 24 hours after randomization.
- Exclusion Criteria:
- • Age below 18 years old;
- • Suspected or confirmed pregnancy;
- • Participation in other interventional trials with similar endpoints;
- • Use of long term home mechanical ventilation;
- • Neurological condition that can prolong duration of mechanical ventilation (i.e.Guillain-Barré syndrome, high spinal cord lesion, amyotrophic lateral sclerosis, multiple sclerosis, or myasthenia gravis);
- • Conditions in which LUS cannot be performed or correctly interpreted (i.e. chest wall abnormalities, morbid obesity, and pre-existing interstitial lung disease);
- • Conditions in which targeting a negative fluid balance is discouraged (i.e. subarachnoid bleeding, severe rhabdomyolysis (CK \> 20.000);
- • Previous participation in this RCT;
- • Patients transferred from another center and invasively ventilated for longer than 24 hours.
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Arnhem, Gelderland, Netherlands
Amsterdam, , Netherlands
Amsterdam, Noord Holland, Netherlands
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Marcus J Schultz, Prof
Principal Investigator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pieter Roel Tuinman, Dr
Principal Investigator
Amsterdam UMC, location VUmc
Frederique Paulus, Dr
Study Director
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Leo MA Heunks
Study Director
Amsterdam UMC, location VUmc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials